We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+9.49%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$142M
AUM Growth
-$445K
Cap. Flow
-$1.24M
Cap. Flow %
-0.88%
Top 10 Hldgs %
76.61%
Holding
63
New
3
Increased
5
Reduced
7
Closed
6

Top Buys

Rank Stock Value
1
BDSX icon
Biodesix
BDSX
+$3.63M
2
ATEC icon
Alphatec Holdings
ATEC
+$806K
3
ELUT icon
Elutia
ELUT
+$608K
4
HALO icon
Halozyme
HALO
+$512K
5
PRTA icon
Prothena Corp
PRTA
+$483K

Top Sells

Rank Stock Value
1
CLR
CONTINENTAL RESOURCES INC.
CLR
+$2.58M
2
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$1.12M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$1.03M
4
NARI
Inari Medical, Inc. Common Stock
NARI
+$726K
5
VTYX
Ventyx Biosciences
VTYX
+$681K

Sector Composition

Rank Sector Weight
1 Healthcare 95.64%
2 Energy 4.26%
3 Consumer Staples 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMGN
26
DELISTED
Immunogen Inc
IMGN
$744K 0.53%
150,000
– –
VTYX
27
DELISTED
Ventyx Biosciences
VTYX
$721K 0.51%
22,000
-23,000
-51% -$681K
BLUE
28
DELISTED
bluebird bio
BLUE
$678K 0.48%
4,900
– –
APLS
29
DELISTED
Apellis Pharmaceuticals
APLS
$621K 0.44%
12,000
– –
HALO icon
30
Halozyme
HALO
$9.14B
$569K 0.4%
+10,000
New +$512K
TSVT
31
DELISTED
2seventy bio
TSVT
$561K 0.4%
59,833
– –
ISEE
32
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$535K 0.38%
25,000
– –
SILK
33
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$529K 0.37%
10,000
– –
ARVN icon
34
Arvinas
ARVN
$517M
$513K 0.36%
15,000
– –
SLNO
35
DELISTED
Soleno Therapeutics
SLNO
$485K 0.34%
245,127
– –
KNSA icon
36
Kiniksa Pharmaceuticals
KNSA
$4.81B
$449K 0.32%
30,000
– –
PTGX icon
37
Protagonist Therapeutics
PTGX
$8.64B
$415K 0.29%
38,000
– –
XENE icon
38
Xenon Pharmaceuticals
XENE
$6.38B
$394K 0.28%
10,000
– –
TXG icon
39
10x Genomics
TXG
$5.49B
$364K 0.26%
+10,000
New +$327K
FOLD
40
DELISTED
Amicus Therapeutics
FOLD
$342K 0.24%
28,000
-10,000
-26% -$113K
KROS icon
41
Keros Therapeutics
KROS
$210M
$336K 0.24%
+7,000
New +$327K
SRPT icon
42
Sarepta Therapeutics
SRPT
$1.78B
$324K 0.23%
2,500
– –
XNCR icon
43
Xencor
XNCR
$1.39B
$320K 0.23%
12,300
– –
KALV
44
DELISTED
KalVista Pharmaceuticals
KALV
$270K 0.19%
40,000
– –
NKTR icon
45
Nektar Therapeutics
NKTR
$2.19B
$267K 0.19%
7,867
-666
-8% -$32.2K
CGEM icon
46
Cullinan Oncology
CGEM
$1.08B
$265K 0.19%
25,114
– –
BCRX icon
47
BioCryst Pharmaceuticals
BCRX
$2.32B
$230K 0.16%
20,000
– –
IFRX icon
48
InflaRx
IFRX
$268M
$217K 0.15%
70,000
– –
GTHX
49
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$217K 0.15%
40,000
– –
GOSS icon
50
Gossamer Bio
GOSS
$68.9M
$215K 0.15%
99,088
-60,000
-38% -$494K
1
2
3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q4 2022 Portfolio in Review

As of Q4 2022, Birchview Capital held 63 positions worth $142M, down 0.31% from $142M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Birchview Capital's Q4 2022 filing shows 3 new, 5 increased, 7 reduced and 6 closed positions. Its largest new stake was Halozyme: 10,000 shares worth $569K. The largest sale was CONTINENTAL RESOURCES INC., an estimated $2.58M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 93% a quarter earlier, followed by Energy and Consumer Staples.

  • Birchview Capital's largest Q4 2022 buy was Halozyme: 10,000 shares worth $569K.
  • Birchview Capital added most to Biodesix in Q4 2022, an estimated $3.63M increase.
  • Birchview Capital's biggest Q4 2022 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $1.12M.
  • Birchview Capital fully exited CONTINENTAL RESOURCES INC. in Q4 2022, selling an estimated $2.58M.
  • Birchview Capital's ten largest holdings make up 77% of its $142M portfolio in Q4 2022.
  • Birchview Capital opened 3 new positions and closed 6 in Q4 2022.
  • Birchview Capital's portfolio value fell 0.31% quarter-over-quarter to $142M.

Based on Birchview Capital's 13F filing for Q4 2022, filed 3 Feb 2023.